Pharmaceutical Technology

NOVEMBER 18, 2023

Aflibercept Biosimilar. is a fusion protein commercialized by Celltrion, with a leading Phase III program in Diabetic Macular Edema.

Biosimilars 40

Biosimilars Diabetes 40

PharmaShots

JUNE 27, 2023

How was the ACR’22 experience for biosimilars for Biogen? We saw Biogen presented multiple results for different biosimilar molecules. Smriti: Can we talk about BIIB800, a tocilizumab biosimilar? Can you please talk about the trial and the results which were presented at ACR’22?

Biosimilars 40

Biosimilars Diabetes Immunization Immunity 40

PharmaShots

APRIL 10, 2023

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. Diabetes, aka diabetes mellitus is a condition that arises when the pancreas fails to produce enough insulin or the cells of the body do not respond to the insulin produced.

Diabetes 40

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

DECEMBER 21, 2020

Boston, US-based Alexion spent a lot of 2019 arguing the merits of remaining independent, saying that while Soliris is approaching the end of its patent life – with heavyweight competitors like Amgen already eyeing the biosimilar market for the drug – Ultomiris and its pipeline could help drives sales to $9 to $10 billion in 2025.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

Pharmaceutical Technology

AUGUST 5, 2022

The diabetic macular oedema (DME) space recently witnessed a new approval; the US Food and Drug Administration (FDA) announced the approval of Coherus’ Cimerli (ranibizumab-eqrn; FYB201), a vascular endothelial growth factor (VEGF) inhibitor therapy. Thus, the biosimilar presented a similar efficacy to the reference product.

Biosimilars 52

Biosimilars Diabetes 52

Pharmaceutical Technology

FEBRUARY 18, 2023

The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The company offers generic medicines and biosimilars through Sandoz. appeared first on Pharmaceutical Technology.

Diabetes 40

Diabetes Generic Medicine Biosimilars Immunization 40

PharmaShots

APRIL 28, 2023

Evecxia Therapeutics Receives Notice of Allowance from the US PTO Covering EVX‑101 Date: Apr 28, 2023 | Tags: Evecxia Therapeutics, EVX‑101, Regulatory, Patent, USPTO, 17/877, 699 Zura Bio Reports $80M Financing and Licensing of ZB-106 from Eli Lilly for Autoimmune Diseases Date: Apr 28, 2023 | Tags: Zura Bio, Eli Lilly, Tibulizumab, ZB-106, Rheumatoid (..)

Diabetes 56

Diabetes Biosimilars 56

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 64

Diabetes Immunization Immunity Biosimilars 64

Pharma in Brief

FEBRUARY 2, 2022

In a recently published discussion paper , an Advisory Panel (the Panel ) convened by the Canadian Agency for Drugs and Technologies in Health ( CADTH ) presents a proposed framework for a potential pan-Canadian formulary. The Panel is asking for feedback on the framework with an online questionnaire. Drug cost was not a consideration.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Diabetes 59

PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

Diabetes 40

Diabetes Biosimilars 40

Pharmaceutical Technology

DECEMBER 20, 2022

The growing competition from generic drugs presents challenges for the top 20 players placing pressure on drug prices. Although AbbVie’s Humira (adalimumab) is set to face biosimilar competition next year, the blockbuster drug reported strong US sales of $4.96 trillion in Q2 2022 to $3.14

Vaccines 52

Vaccines Diabetes Drug Pricing Biosimilars 52

PharmaShots

MARCH 29, 2023

Some companies accept the offered period and open doors to biological drugs or biosimilars. The drug selectively inhibits the phosphorylation of VEGFR cells, c-kit and PDGFR-ß As of now, there are no generic versions available for the drug at present. As of now, there are no the US FDA approved biosimilars available for Actemra.

Biosimilars 49

Biosimilars Diabetes Chemotherapy Immunization 49

PharmaShots

JUNE 9, 2023

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

Biosimilars 40

Biosimilars Diabetes 40

pharmaphorum

JANUARY 5, 2021

It varies by country and by therapy area, but is pervasively present, and its consequences play out both now and long into the future. In the long term, the health impact of delayed or absent treatment for patients could play out as more severe or advanced disease presentation, higher co-morbidities and even earlier deaths.

Hospitals 105

Hospitals Vaccines Pharmaceutical Companies Pharmaceutical Companies 105

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 40

Diabetes Immunization Immunity Biosimilars 40

PharmaShots

FEBRUARY 27, 2023

The theme of the event was Innovation, Advanced Technology, Current Challenges & Opportunities in Pharma & Healthcare Industry under which a series of presentation sessions and panel discussions were held related to pharma trends, APIs, policy reforms, AI, metaverse, current regulatory trends and the direction of pharma and drug discovery.

Biosimilars 40

Biosimilars Diabetes Packaging Hospitals 40

PharmaShots

APRIL 3, 2023

APRINOIA & ROSS will become a wholly owned subsidiary of the combined company, APRINOIA Therapeutics & the combined company is expected to be traded on Nasdaq or NYSE APRINOIA focused on developing a pipeline of highly specific CNS diagnostics & therapeutics, incl. APN-1607 & APN-005 for neurodegenerative disease. vs 9.2mos.)

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40

Putting Patients First Blog

JANUARY 27, 2025

However, the scope and complexity of the proposed rule may present implementation challenges. The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

RX Note

FEBRUARY 23, 2023

Threadworm - Night-time perianal itching is the classic presentation Oral Thrush - Unusual in healthy adults Faecal Incontinence - Unintentional passage of stool Pouching Systems - Available as one-piece or two-piece systems Eye Dry Eye - Evidence of superior efficacy among any of the ophthalmic lubricants is lacking.

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Community Pharmacies Labelling Chemotherapy 58

Safe Biologics

APRIL 10, 2023

ASBM Presents at WHO 76th INN Consultation On March 28th, ASBM participated in the World Health Organization’s 76th Consultation on International Non-proprietary Names (INN) for Pharmaceutical Substances, held in Geneva, Switzerland. Send Comments on the Guidance to CMS here. Read the WHO’s summary of the 75th INN Consultation here.

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130

Express Pharma

JANUARY 3, 2025

While India was able to leverage the 2008 patent cliff of small molecules, the same playbook will not work for biologics and biosimilars. Many biopharma companies in India have already leveraged the biosimilar patent cliff. Biocon became the first company from India to launch its biosimilar Hulio in the US in July 2023.

Biosimilars 105

Biosimilars Vaccines Diabetes 105